🚀 New in @ESC_Journals our “AI in cardiovascular pharmacotherapy—applications & perspectives.” Link https://t.co/2QLhugIkmW 💊 AI will revolutionize cardiology, but what is the state of the art in CV pharmacotherapy? Is it ready for prime time? Let’s dive in ⬇️🧵 1️⃣/12

It was previously described in @JACCJournals , & apparently is a benign finding with @bostonsci Watchman FLX owing to the different sewing of the fabric. We will program follow-up to evaluate if this impair endothelization. https://t.co/DQ7Y77mhS3

‘Wind Sailing Effect’ after #LAAO today. Watchman FLX implant w/o issues (final compression 20% 🔔 shape). After release a clear billowing of the device fabric was evident @mmamas1973 @ignamatsant @AnderRegueiro @AsmaratsL @giampieroviz @g_giustinoMD @pabl0salinas @mirvatalasnag

Honored to be a finalist for the #TCT #LinnemeierAward, the world’s top recognition for interventional cardiologists under 40. Grateful to all mentors & colleagues in Messina, Rotterdam, Siracusa, Barcelona and Malaga who made this path possible. The best is yet to come. ❤️

🏆 Congratulations to Gennaro Giustino, MD (@g_giustinoMD) for receiving the Thomas J. Linnemeier Spirit of #InterventionalCardiology Young Investigator Award at #TCT2025! 🌟Your work is shaping the future of cardiovascular care. 👏 A huge shoutout to all the incredible

Celebrate the rising stars 💫 of #interventionalcardiology as we honor the finalists for the Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award and announce this year’s recipient!🌠 #CardioX #CardioTwitter #CardioEd #CardioResearch @Costa_F_8

Left main thrombosis PCI without IMPELLA 🍕

🙏 Grateful beyond words to be selected among the finalists of the Linnemeier award at TCT. It will be an honor to share the stage with such a talented group of colleagues and friends. See you in San Francisco! #TCT2025

The Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award has launched the careers of the field’s brightest stars. ✨ 👏 Congratulations to this year’s outstanding finalists! https://t.co/70jwPAvEuJ Join us at #TCT2025 as we reveal this year’s

This is an important topic & was the focus of the Research Academy #ELP @TCT_ME_ 2025 @TCTConference It was an opportunity to introduce the regional community to @JACCJournals We had an incredible faculty discussing this very topic with @JACCJournals @_KSU 👇👇👇 2026

🎉 Congratulations to our faculty member Dr. Francesco Costa @Costa_F_8 for being nominated as a finalist for the international Linnemeier Award, which recognizes emerging global leaders in interventional cardiology. 💪 So proud!!! @HUVV_SAS @_ibima 🔗 https://t.co/CgLc2koCUU

🎉 Felicitamos a nuestro facultativo Dr. Francesco Costa @Costa_F_8 por su nominación como finalista al premio internacional Linnemmeier, que reconoce a los líderes mundiales emergentes en cardiología intervencionista 💪Orgullo!!! @HUVV_SAS @_ibima 🔗 https://t.co/M9kLlJyfs8

Some additional slides from the @MonteHeart Lecture Talk based on the outstanding work of @ekoikonomou @AryaAminorroaya @rohan_khera @AndreasKarwath et al in the field, and our ongoing #ORACLE project.

An honor being invited to @MonteHeart Lectures for a talk on #AI in #cardiovascular #pharmacotherapy, based on our recent work in @ESC_Journals. Thanks @CardioMDPhD for the kind invitation and for the great work you are doing. Below some key slides in the thread ⤵️

Welcome to another @MonteHeart Imaging and Clinical Lectures Friday, September 26, 2025 From 12:00 pm EST – 1:00 pm EST Link --> https://t.co/YsJhZrqOzL

I think I have a positive bias toward the PARTHENOPE trial, not only because I was part of the Steering Committee and deeply respect the work behind it, but also because it does something rarely done when validating risk scores: randomization. Usually, we see validation based on

As OAC pts are HBR by definition, this align with our prior meta in HBR pts, in which we observed longer DAPT was associated with an excess of CV death in this population. Speculating on the possible mechanisms is fascinating, more research needed. https://t.co/odOjfO96eZ

One might expect that ASA on top of OAC increases bleeding, it is Interesting to see that (most importantly) drives an excess of hard ischemic endpoints (mostly CV death) in a placebo controlled study. So too much antithrombotic do not mitigate but exacerbate ischemic events ⬇️

Cancer and nuances thereof (terminal, active, remission, cured) is of great importance and should factored in for treatment decisions @mmamas1973

Great to see the results of the PARTHENOPE published: personalized DAPT is superior to the (in)famous 12m DAPT. But An answer=100 new questions: tailor based on bleeding risk? Updated score? Congrats @piccoloraf @esposito on their leadership in this all Southern Italy study 🇮🇹

A personalized DAPT was superior to standard DAPT after PCI.📌Here are the slides presented at: #ESCCongress @mmamas1973 @mirvatalasnag @rwyeh @djc795 @CMichaelGibson @SripalBangalore @Costa_F_8 @pash22 @Ahmed43101178 @Hragy @SABOURETCardio @drjohnm @espogiov @JACCJournals